Levagen+®

The Next-Generation Palmitoylethanolamide (PEA)

A patented, highly bioavailable form of palmitoylethanolamide (PEA), clinically studied to reduce inflammation, joint pain, muscle recovery time and to improve sleep.

What is Levagen+® Good For?

Levagen+® is a naturally occurring fatty acid amide that activates the endocannabinoid system (ECS) and the peroxisome proliferator-activated receptor α (PPAR-α) that is clinically shown to reduce pain, inflammation and improve sleep quality.

 

Using LipiSperse® delivery technology, Levagen+® overcomes the low solubility and absorption issues of standard PEA, resulting in clinically proven higher bioavailability.

 

Levagen+® supplementation may help to:

  • Decrease joint pain

  • Reduce migraine pain and duration 

  • Reduce inflammation by activating PPAR-α and transient receptor vanilloid type 1 (TRPV1)

  • Improve allergic rhinitis symptoms by reducing histamine and several inflammation markers

  • Muscle recovery by lowered myoglobin and blood lactate levels

  • Reduce upper respiratory tract infections

  • Fall asleep faster and improve cognition upon waking

What is Palmitoylethanolamide (PEA)?

PEA is an endogenously produced fatty acid amide first discovered in the 1950s. It naturally regulates inflammation and pain pathways, acting as a protective molecule during stress and injury.

 

Levagen+® enhances this natural effect by delivering PEA in a highly absorbable form, backed by multiple clinical trials.

What is the Recommended Daily Dose of Levagen+®?

Human studies support 300 mg daily of Levagen+® supplementation for joint pain, lowering inflammation, and improving sleep. Doses up to 600 mg/day have been studied for enhanced benefits.

Things to Know

Source

Palmitoylethanolamide (naturally occurring fatty acid amide)

Technology

Patented LipiSperse® delivery system for enhanced absorption

Region

Developed and clinically validated by Gencor, an innovation leader in nutraceutical ingredients

Data

Supported by multiple randomised, double-blind, placebo-controlled human clinical studies

Levagen+® in Detail

Clinical Dose
Clinical Dose

300 mg

Source
Source

Palmitoylethanolamide (PEA)

Technology
Technology

LipiSperse® delivery system improves solubility and bioavailability of PEA

Key Benefits
Key Benefits
  • Clinically proven to improve absorption vs. standard PEA
  • Lowering joint pain
  • Reduces inflammation and aids recovery from exercise
  • Helps to fall asleep and better cognition upon waking
  • Endocannabinoid system support without psychoactive effects
Data
Data

Validated by peer-reviewed clinical trials for pain management, recovery, sleep, and even for allergy management.

Your Questions About Levagen+®

Reach us arrow_forward
Levagen+® is a patented, highly bioavailable form of PEA (palmitoylethanolamide), enhanced with LipiSperse® technology.
It helps to manage inflammation, joint pain and improves sleep.
Levagen+® is clinically shown to be more bioavailable thanks to LipiSperse® technology, delivering consistent and effective results.
PEA is well tolerated with no significant side effects reported at clinical doses.
Yes, PEA works on overlapping pathways with the ECS but is non-psychoactive, making it a safe complement to CBD.

Discover your formula of ingredients

No two people are the same. That’s why your formula is uniquely yours. We select the most effective ingredients based on your health data, lifestyle, and goals — ensuring your capsules are both efficient and safe.

Discover your formulaarrow_forwardMembership planarrow_forward

References

The Science That Supports Us

Cognitive and Neurological Support

Briskey, D., Ebelt, P. and Rao, A. (2023) ‘The effect of Levagen+ (palmitoylethanolamide) supplementation on symptoms of allergic rhinitis—a double-blind placebo-controlled trial’, Nutrients, 15(23), p. 4940. doi:10.3390/nu15234940. 

Mental Health

Briskey, D. et al. (2024) ‘Effectiveness of palmitoylethanolamide (Levagen+) compared to a placebo for reducing pain, duration, and medication use during migraines in otherwise healthy participants—a double-blind randomised controlled study’, Pharmaceuticals, 17(2), p. 145. doi:10.3390/ph17020145. 

Nerve Repair

Briskey, D., Roche, G. and Rao, A. (2021) ‘The effect of a dispersible palmitoylethanolamide (Levagen+) compared to a placebo for reducing joint pain in an adult population – a randomised, double-blind study’, International Journal of Nutrition and Food Sciences, 10(1), p. 9. doi:10.11648/j.ijnfs.20211001.12. 

Immune System Support

Mallard, A. et al. (2020) ‘The effect of orally dosed levagen+TM (palmitoylethanolamide) on exercise recovery in healthy males—a double-blind, randomized, placebo-controlled study’, Nutrients, 12(3), p. 596. doi:10.3390/nu12030596. 

Immune System Support

Petrosino, S. and Di Marzo, V. (2016) ‘The pharmacology of Palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations’, British Journal of Pharmacology, 174(11), pp. 1349–1365. doi:10.1111/bph.13580. 

Immune System Support

Rao, A., Skinner, R. and Briskey, D. (2023) ‘The efficacy of palmitoylethanolamide (levagen+) on the incidence and symptoms of upper respiratory tract infection—a double blind, randomised, placebo-controlled trial’, Nutrients, 15(20), p. 4453. doi:10.3390/nu15204453.

Immune System Support

Rao, A. et al. (2021) ‘Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study’, Sleep Science and Practice, 5(1). doi:10.1186/s41606-021-00065-3.